

Edgar Filing: Pharma-Bio Serv, Inc. - Form 8-K/A

Pharma-Bio Serv, Inc.
Form 8-K/A
August 14, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2006

Pharma-Bio Serv, Inc.
(Exact name of registrant as specified in its charter)

Delaware -----	0-50956 -----	2
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer

373 Mendez Vigo, Suite 110, Dorado, Puerto Rico 00646
(Address of principal executive offices)

Registrant's telephone number, including area code: (787) 278-2709

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 4.01 Changes in Registrant's Certifying Accountants.

On July 28, 2006, Kevane Soto Pasarell Grant Thornton LLP ("Kevane") advised us that it is resigning as our independent registered accounting firm as of the completion of the third quarter interim review.

Kevane was the independent accountant for Plaza Consulting Group, Inc. ("Plaza") for the fiscal years ended October 31, 2005 and 2004. Kevane's report for these periods did not contain an adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles. Plaza was acquired by Pharma-Bio Serv, Inc. (the "Registrant") on January 25, 2006. During the two most recent fiscal years (for Plaza) and any subsequent interim period (for the Registrant) through the date of resignation, there were no disagreements with Kevane on any matter of accounting principles

Edgar Filing: Pharma-Bio Serv, Inc. - Form 8-K/A

or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Kevane, would have caused it to make reference to the subject matter of the disagreements in connection with its reports.

Item 9.01 Financial Statements and Exhibits.

Exhibits

16.1 Letters from Kevane Soto Pasarell Grant Thornton LLP

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMA-BIO SERV, INC.
(Registrant)

Date: August 11, 2006

/s/ Manuel O. Morera

Manuel O. Morera, Chief Financial Officer